Browse the evidence

Long-term caloric restriction (25% reduction for 24 months) induces metabolic adaptation (adaptive thermogenesis) in sleeping energy expenditure that exceeds predictions based on changes in body mass alone, with the effect persisting at 24 months when assessed using advanced MRI-derived organ and tissue mass models.

If you restrict calories by 25% for two years, your body will adapt by lowering its energy expenditure more than expected from weight loss alone. This 'metabolic adaptation' is real and persists, especially when looking at organ-level changes. To manage this, focus on preserving muscle mass through resistance training and protein intake, as the study shows lean tissue loss is part of the equation, though not the whole story of metabolic slowdown.

While fat-free mass gains are similar, 16:8 TRE results in less fat mass accumulation and lower total training volume compared to continuous feeding during a caloric surplus.

Be aware that if you switch to an 8-hour eating window, you might naturally train for less total volume and accumulate slightly less fat than if you ate all day, even in a surplus. This isn't necessarily bad—it might mean you are more efficient with your energy—but it is a trade-off to consider if your goal is maximum fat gain (bulking).

Obesity increases perioperative morbidity and technical complexity in gastrointestinal cancer surgery, including higher rates of anastomotic leak and surgical site infection.

If you are obese and undergoing gastrointestinal cancer surgery, discuss the increased risk of complications with your surgeon. Preoperative weight loss may be recommended to reduce these risks.

Sustained weight loss of at least 5% achieved through pharmacotherapy or bariatric surgery is associated with a reduced risk of obesity-related cancers.

To reduce cancer risk, weight loss must be sustained over the long term. Losing at least 5% of body weight and keeping it off is associated with lower cancer risk. For those who struggle to maintain weight loss, pharmacotherapy or bariatric surgery can help sustain the loss, thereby preserving the cancer-protective benefits.

Orlistat, a lipase inhibitor, promotes modest weight loss (approx. 2-3 kg over 24 weeks) by blocking the absorption of dietary fat, but is associated with gastrointestinal side effects and potential fat-soluble vitamin deficiencies.

Orlistat is an older weight loss drug that works by blocking fat absorption. It leads to modest weight loss (around 2 kg over 6 months) and requires taking a capsule with each meal. Common side effects include oily stools and abdominal pain, which can be managed by keeping dietary fat low. You should also take a multivitamin at a different time of day to avoid nutrient deficiencies.

Very-low-carbohydrate diets enhance human T-cell immunity by inducing ketone body production (specifically beta-hydroxybutyrate), which reprograms T-cells to favor oxidative metabolism, improves cellular energy supply, and increases T memory cell formation.

If you reduce carbohydrate intake significantly, your body produces ketones like beta-hydroxybutyrate. This shift can reprogram your T-cells to use energy more efficiently via oxidative metabolism, potentially enhancing their ability to form long-term memory and respond to pathogens.

Weight loss mitigates the metabolic risk associated with high refined grain and carbohydrate intake, whereas weight gain exacerbates it.

If you are gaining weight, reducing refined grains is crucial to lowering metabolic syndrome risk. If you are losing weight, keeping refined grains below the median intake further reduces risk. Weight management modulates the impact of grain quality.

Following behavioral weight loss, the body enters a physiological state characterized by adaptive thermogenesis (declines in energy expenditure beyond those attributable to changes in body composition) and increased energy intake, which drive weight regain.

After losing weight, your body biologically fights to regain it by lowering your energy expenditure and increasing hunger. This is a normal physiological response, not a personal failure. To maintain weight loss, you must account for these biological changes, likely requiring ongoing behavioral support and potentially adjusted energy intake/expenditure strategies, rather than relying on the same intensity of effort used during the weight loss phase.

Using different prediction equations (Katch-McArdle vs. BIA-derived) to estimate Resting Metabolic Rate (RMR) during weight loss yields significantly different conclusions regarding the presence of metabolic adaptation (MA), with Katch-McArdle suggesting increased metabolic efficiency (increased aRMR) while BIA suggests decreased efficiency (decreased aRMR).

When tracking weight loss, do not rely on a single prediction equation to judge your metabolic health. This study shows that different formulas can contradict each other regarding metabolic adaptation. To minimize this error, prioritize preserving fat-free mass (muscle) through adequate protein intake (approx. 2.0 g/kg FFM as used in the study) and resistance training, as this stabilizes the metabolic rate more reliably than any single calculation method.

Weight cycling (losing and regaining weight) is associated with unfavorable cardiometabolic profiles and increased cardiovascular disease risk.

Avoid yo-yo dieting. While losing weight is good, regaining it repeatedly is worse for your heart than staying at your starting weight. Focus on maintaining your weight loss through sustainable lifestyle changes.

Intragastric balloons (IGB) are effective for weight loss but carry risks of dehydration, readmission, and reintervention, with saline-filled balloons outperforming air-filled ones.

If lifestyle changes haven't worked, an intragastric balloon can be a helpful bridge. Choose a saline-filled balloon over an air-filled one for better results. Be prepared for a 6-12 month commitment and take prescribed stomach acid reducers to prevent discomfort. The risk of serious complications is low, but dehydration is a common side effect.

Tirzepatide treatment (5-15 mg weekly) significantly reduces serum uric acid (SUA) levels in adults with obesity or overweight, with weight reduction explaining 72.7% of this effect.

If you have obesity or overweight and are concerned about gout or high uric acid, tirzepatide (a once-weekly injection) can significantly lower your uric acid levels. Most of this benefit comes from the weight loss it causes, but it may also have direct effects. This makes it a potentially useful tool for managing gout risk in people with obesity, in addition to helping with weight loss.

Ramadan fasting significantly impairs anaerobic power (Wingate peak and mean power) and upper-body strength (bench press), but does not significantly affect lower-body maximal strength (leg press), explosive power (countermovement jump), or isometric strength (handgrip).

During prolonged fasting, expect a drop in your ability to perform high-intensity, short-duration efforts (like sprints or heavy upper-body lifts). Your leg strength and vertical jump may remain stable, but prioritize recovery and nutrition strategies for anaerobic tasks.

Exercise therapy reduces AHI and improves daytime sleepiness in OSA patients, often independently of significant weight loss, through mechanisms such as reduced leg fluid shift and improved upper airway neuromuscular control.

Incorporate 150 minutes of moderate aerobic exercise (like brisk walking) and resistance training twice a week into your routine. This can reduce the severity of your sleep apnea and improve daytime sleepiness, even if you don't lose a lot of weight. The benefits come from improved airway muscle control and reduced fluid shifts in your neck.

Modest weight loss (5%) in Type 2 Diabetes improves cardiovascular risk factors (lipids, glucose) but evidence for reducing actual cardiovascular mortality or events is mixed and inconclusive.

Losing 5% of your body weight if you are overweight with Type 2 Diabetes is highly recommended to improve your blood sugar, cholesterol, and overall heart health profile. However, do not assume this single change will eliminate your risk of heart attack or stroke; it works best when combined with blood pressure and glucose management.

Caloric restriction interventions produce significant short-term weight loss but are associated with significant weight regain and increased hunger/appetite over the long term (12+ months).

If you use calorie counting, expect your hunger to increase as you lose weight. This is a biological defense mechanism, not a lack of willpower. To avoid the 'yo-yo' effect, prioritize moderate deficits (e.g., 1300-1500 kcal) over extreme ones, and focus on high-satiety foods. Long-term success requires a plan that manages hunger, not just a number on a scale.

Ketogenic diets produce greater short-term weight loss compared to control diets when caloric intake is not restricted (ad libitum), but this advantage disappears when calories are matched, resulting in weight loss similar to control diets.

If you choose a ketogenic diet, expect faster initial weight loss likely due to reduced calorie intake, not magic. If you match your calories to a standard diet, you will lose weight at the same rate. Focus on maintaining a caloric deficit regardless of macronutrient ratio.

Moderate breakfast energy intake is associated with a reduced risk of major cardiovascular events and stroke, regardless of whether breakfast is skipped.

Eating a moderate amount of calories at breakfast is associated with lower heart disease and stroke risk. It is not just about eating breakfast, but about how much you eat.

Low-carbohydrate diets induce significantly greater early-phase calorie restriction (approx. 162 kcal/d more) compared to low-fat diets, but this advantage dissipates over time, resulting in no long-term difference in energy intake or weight loss.

If you start a low-carb diet, expect a strong initial drop in hunger and calorie intake, which is normal. However, do not expect this advantage to last forever; your appetite will gradually increase as you lose weight, and your calorie intake will eventually match that of someone on a low-fat diet. Focus on finding a sustainable carbohydrate level you can maintain long-term, rather than relying on the initial 'magic' of strict restriction.

Bariatric surgery is the most effective, sustainable, and generally safe therapy for severe obesity (BMI ≥ 35 kg/m²) when lifestyle and pharmacological treatments have failed.

For severe obesity (BMI ≥ 35) where lifestyle and drug treatments have failed, bariatric surgery is the most effective and sustainable option. It is indicated for BMI > 30 with type 2 diabetes. Risks must be carefully weighed against benefits, and lifelong follow-up is required.

Bariatric surgery (Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) provides effective and sustainable weight loss, with Roux-en-Y showing greater long-term excess weight loss but higher morbidity.

If you have severe obesity (BMI >40 or >35 with health issues), surgery is a highly effective option. Gastric Bypass leads to more weight loss than Sleeve Gastrectomy but has higher risks. Discuss the trade-offs with your surgeon.

Preobese individuals with a low relative resting metabolic rate (RMR) normalized for fat-free mass are at higher risk for future weight gain and obesity.

If you are preobese, your metabolic rate relative to your muscle mass might be lower than average, making you more prone to weight gain. Monitoring your metabolic rate or focusing on building fat-free mass could be beneficial strategies for prevention.

Lifestyle interventions (caloric deficit and exercise) remain the cornerstone of obesity care but are often insufficient for long-term maintenance without pharmacotherapy.

Start with a 500-750 kcal daily deficit and 150 minutes of moderate exercise per week. Aim for 5-10% weight loss in 6 months. If you struggle to maintain this, consider adding pharmacotherapy, as lifestyle changes alone are often insufficient for long-term maintenance.

Bariatric surgery still outperforms pharmacotherapy in terms of absolute weight loss magnitude and durability, with surgery yielding approximately five times more weight loss in real-world cohorts.

While incretin drugs are powerful, bariatric surgery still achieves greater weight loss on average (25-35% vs 15-22%). If your goal is maximum possible weight loss and you are a surgical candidate, surgery may still be the most effective option. However, if you fear surgery or have contraindications, polyagonists offer a highly effective, non-surgical path to significant weight loss.